Duke-Margolis Institute for Health Policy

We are excited to officially announce that Duke has elevated Duke-Margolis to a University Health Policy Institute! With this new recognition, Duke-Margolis will continue to address timely health policy challenges; amplify Duke’s collective ability to support research and education that impacts health policy locally, nationally, and across the globe; and deepen Duke’s recruitment and retention of dynamic faculty and scholars who will lead, research, and explore the most pressing health care challenges of the future. Read the press release here: https://duke.is/z/aqgs

Join FDA’s Center for Drug Evaluation and Research and Duke-Margolis Institute for Health Policy on December 12, 2024 for a public hybrid workshop, Optimizing the Use of Real-World Evidence in Regulatory Decision-Making for Drugs and Biological Products- Looking Forward, to discuss potential next steps to promote the continued evolution and consistent application of real-world data in drug development. We encourage in-person participation. Please register by Friday, December 6, 2024. Registration is free and based on available space due to limited seating. Early registrants will have priority. Register ?? https://lnkd.in/eRf_pjeN

Our next event is just a few weeks away! Duke-Margolis and Duke Health are hosting a webinar on November 18 to explore key findings from our recently published white paper, which examines how health systems are addressing governance for artificial intelligence. Learn more and register here: https://duke.is/8/3t5p

In their new Forefront article, Rachel Bonesteel, Sara Debab, William K. Bleser, Frank McStay, Robert S. Saunders, and Mark B. McClellan from the Duke-Margolis Institute for Health Policy present timely guidance and recommendations for CMS on the design and implementation of REACH, informed by literature review and conversations with REACH participants and other expert stakeholders about successes, challenges, and opportunities for improvement. "ACO REACH is the largest Innovation Center model and has seen an increase in beneficiaries from GPDC’s 2.0 million in 2022 to 2.6 million in 2024, including significant increases in safety-net provider participation. It is a more advanced alternative payment model than the Center for Medicare’s (CM’s) permanent ACO model, the Medicare Shared Savings Program (MSSP), offering prospective payments and global risk. Experts have noted the REACH program is a major step forward in incorporating multiple equity design and implementation elements directly into an advanced VBP model. Finally, it provides an opportunity to expand benefits available to traditional Medicare beneficiaries as an alternative to the additional benefit flexibility in Medicare Advantage (MA) plans." Read the full article here: https://bit.ly/3Uy1SSP

Duke-Margolis Institute is looking for a an accomplished administrative manager with meaningful higher education fundraising experience and an aptitude for understanding organizational dynamics and vision, as well as the shifting landscape of higher education and trends in philanthropic giving. Learn more: https://lnkd.in/eg-MVpc5 #job #jobposting #hiring #fundraising #jobseeker #recruitment #jobopening #hire

We're gearing up for respiratory virus season with this new virtual workshop, where we will present our refined virus transmission reduction framework alongside proposed policy reforms to improve evidence generation on indirect benefits and population health outcomes. We will also explore how to leverage existing decision-making capacity by the U.S. Food and Drug Administration and the Centers for Medicare & Medicaid Services. Join us on December 9: https://duke.is/j/ey9e

Postdoctoral Associate Kun Li co-authored a paper that has just been published in JAMA Health Forum. The authors explored how a change in ownership for home health agencies might impact quality of care:

Next month, Duke-Margolis and the U.S. Food and Drug Administration will convene a virtual workshop to review data regarding risks associated with the use of medication in the antipsychotic class in older adults with behavioral and psychiatric symptoms associated with dementia. Attendees will hear reflections on available evidence and further considerations related to the assessment of risks associated with the use of antipsychotics within this patient population. Join us on December 10: https://duke.is/2/4dtc

Don't miss our upcoming event! Duke-Margolis will host a hybrid workshop, under a cooperative agreement with the U.S. Food and Drug Administration, to discuss the latest developments in and future opportunities for the Sentinel Initiative. Though our in-person venue has reached capacity, we invite you to join us virtually on November 7 to learn more. Check out the final agenda and register here: https://duke.is/m/gxk9

Duke Health AI Evaluation & Governance Program’s Nicoleta Economou, PhD, and the Duke-Margolis Institute for Health Policy’s Christina Silcox, PhD, and Valerie J. Parker, MSc-GH, have collaborated on an important white paper, titled "AI Governance in Health Systems: Aligning Innovation, Accountability, and Trust." The paper examines the transformative potential of AI in health care and draws valuable insights from US health systems on AI governance, identifying both core governance principles and diverse implementation strategies. The paper also provides actionable guidance for health systems and policymakers on establishing and standardizing AI governance, aiming to democratize trustworthy AI across the health care landscape. The recommendations focus on ensuring that all health systems, including those with limited resources, receive structured guidance that promotes best practices, accountability, and equitable access to the benefits of AI advancements. You can read the full white paper here: https://lnkd.in/eehgSVim Duke Health; Duke University School of Medicine; Duke Clinical Research Institute